Online inquiry

IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11056MR)

This product GTTS-WQ11056MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR&LGR5 gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001346897.2; NM_001277226.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956; 8549
UniProt ID Q504U8; O75473
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11056MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3526MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BART
GTTS-WQ7332MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ6083MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ13692MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ5785MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ3077MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ10504MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ12825MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMS721
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW